TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06287268

Intervention type: OTHER
Intervention: eltrombopag
Description: This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.
Study: NCT06688448

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dafodil prosthesis
Description: Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aortic Valve Replacement - Inspires Resilia prosthesis
Description: Surgical aortic valve replacement (SAVR) will be performed following standardized protocols to ensure consistency and optimize patient outcomes. Under general anesthesia, a median sternotomy will be conducted to access the aorta. Cardiopulmonary bypass (CPB) will be initiated, and the aorta will be cross-clamped to facilitate the safe removal of the existing prosthesis. After excising the deteriorated valve and removing any calcification, the new bioprosthetic valve will be implanted after randomized.
Study: NCT06708260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403, low dose
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENN0403, high dose
Description: ENN0403 capsules will be orally administered once a day for 12 weeks.
Study: NCT05317819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Treatment for hepatocellular carcinoma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for hepatocellular carcinoma
Study: NCT06500273

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cemacabtagene ansegedleucel
Description: An allogeneic CAR T cell therapy targeting CD19

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cemacabtagene ansegedleucel
Description: An allogeneic CAR T cell therapy targeting CD19

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-647
Description: A monoclonal antibody targeting CD52

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy for lymphodepletion

Intervention type: DEVICE
Group type: OTHER
Intervention: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™
Description: A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.
Study: NCT06742190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empasiprubart
Description: Intravenous infusion of empasiprubart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Empasiprubart
Description: Intravenous infusion of empasiprubart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIG (Intravenous Immunoglobulin)
Description: Intravenous infusion of IVIg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Empasiprubart-placebo
Description: A placebo resembling the empasiprubart treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIg-placebo
Description: A placebo resembling the IVIg treatment
Study: NCT06744816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qutenza Patch
Description: Given topical
Study: NCT06759116

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ml saline)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 50 mcg fentanyl)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group
Description: The patient receive unilateral ultrasound guided combined IPACK and ACB with bupivacaine only. two syringes , one for each block , each one contains (20 mL of 0.25% bupivacaine and 1 ug/kg dexmedetomidine not exceeding 100 ug (to be completed to 1mL with normal saline if needed). )
Study: NCT06765278

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Patients will receive an Interscalene brachial plexus block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior glenoid nerve block
Description: Patients will receive an anterior glenoid nerve block.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: Patients will receive a pericapsular nerve group (PENG) block.
Study: NCT06773364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Intervention group - to commence IV levetiracetam 500mg as a single bolus in the ambulance, and then to continue as levetiracetam 500mg bid orally after admission to hospital in those with confirmed acute stroke for the next 14 days (at least 7 days if either dead or discharged from hospital if earlier). They will also receive standard management of acute stroke, whether the final diagnosis is ischaemic or ICH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Guide-recommended management
Description: To receive stroke management according to standard local guidelines, but to avoid prophylactic use of an anti-seizure drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The lying flat (0°) head position
Description: Lie flat (0°) - in the ambulance as soon as possible until arrival at hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The sitting-up (≥30°) head position
Description: Sit up(30-60°) - in the ambulance as soon as possible until arrival at hospital.
Study: NCT06774261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenserine
Description: Phenserine is a next generation AChE inhibitor being developed for the treatment of AD. Unlike currently marketed AChE inhibitors, it has additional mechanisms of action that also include a mediating effect on cell death pathways and anti-amyloid activity, which may confer disease-modifying effects in people with AD.~Phenserine was originally identified and developed by the United States (U.S.) National Institute of Aging (NIA), part of the U.S National Institute of Health (NIH).~The study intervention will be open label. No blinding will be performed. Participants and site staff will, however, will be blinded to the results of the exosome and blood/CSF biomarker evaluations until the study is completed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil (Aricept®)
Description: The substance donepezil (under the brand name Aricept®) is a resale product. No additional manufacturing or labeling measures is necessary for this study.~The NIMP, donepezil will be available in 5 mg and 10 mg strengths (table 3) and will be dispensed by the local pharmacy at the hospital where the participant in the donepezil arm is included. We have based the use of donepezil as a treatment in the study on the original product from Pfizer, but it is also possible to use generic products of donepezil if this is what the local pharmacy has for dispensing. Participants randomized to treatment with donepezil will follow the treatment plan according to the patient information leaflet. . These tablets are approved for clinical use and comply with all relevant safety and efficacy standards.
Study: NCT06772766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Ascending IV doses administered per protocol
Study: NCT04764474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-306
Description: Administered orally QD in a 28-day continuous dosing treatment cycle
Study: NCT06772766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Ascending IV doses administered per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3011 placebo
Description: Ascending IV doses administered per protocol
Study: NCT06774092

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT06774950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-patient quality circle
Description: Intervention: (To be compared with standard care)~1. Interprofessionnal meeting per neighbourhood: (beforehand) Therapeutic patient education (TPE) training for healthcare professionals~2. Physician-patient quality circle t0 Group sessions (n= 3 to 6 patients) with doctor and therapeutic patient education specialist Clinical measurements - CM (incl. HbA1c, body composition, blood pressure). PROM evaluation questionnaires (EQ5D\&DIABQ)~3. Development of individualised T2D programme: with case manager~4. Quarterly follow-up: t3, t6, t9 months PROM follow-up (DIABQ\&PHQ9) +CM.~5. Evaluation of experience: t12 \& t18 months PREM\&PROM evaluation questionnaire +CM
Study: NCT06774963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNCB74
Description: LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNCB74
Description: LNCB74 is an antibody drug conjugate being evaluated as a potential treatment for participants with advanced solid tumors. Participants will receive LNCB74 into the vein (IV; intravenously) in 21-day dosing cycles. Participants will continue treatment in the absence of unacceptable toxicities and unequivocal disease progression.
Study: NCT06774859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baloxavir Marboxil
Description: Baloxavir marboxil will be administered as oral suspension: 2 milligrams per kilograms (mg/kg) (if weight \< 20 kg), 40 mg (if weight ≥ 20 kg to \< 80 kg), or 80 mg (if weight ≥ 80 kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: Oseltamivir will be administered as oral capsule: 30 mg (if weight ≤15 kg), 45 mg (if weight \> 15 kg to ≥ 23 kg), 60 mg (if weight \> 23 kg to ≤ 40 kg) or 75 mg (if weight \> 40 kg), twice daily (BID) for 5 days.
Study: NCT06772389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Tutoring
Description: Peer tutoring is defined as individuals who are in a similar social group and are not professional teachers helping each other to learn and teach. For peer tutoring, the subject of EFM was grouped under 6 headings. The students in the Peer tutoring group were divided into groups of 6. The researcher explained a heading of the EFM subject to each of these 6 groups. Then, new groups were formed by taking one student from each group. In these new groups, each student explained his/her own subject to his/her peers.
Study: NCT06773169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IAMABLE web-based app
Description: The Intervention Group will use the IAMABLE app for 4 months. IAMABLE users identify activities that they are having difficulty with because of their health problem and set goals they want to work toward. Self-management (SM) modules help them reach their goals, providing information and rehabilitation strategies about exercise, fall prevention, fatigue management, pain management, physical activity, and stress management. Users complete a self-assessment associated with each module, and receive tailored recommendations that guide them to access relevant module topics. Users create 7-day action plans using the strategies in the module to address their activity goals. Users receive automated notifications when it is time to evaluate action plans and activity goals, as well as weekly messages to remind them to engage with the app. Users have access to therapist support using the Ask a Therapist feature and receive individual consultations in response to queries about SM.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: General health information
Description: The Control Group will receive a monthly email with general health information (not specific to rehabilitation or chronic diseases) for 4 months. Topics will include Nutrition, Vision Care, Foot Care, Hearing, Skin Care and Oral Care. Each email will include an introduction to the topic and links for additional information.
Study: NCT06772610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib group
Description: Ensartinib 200 mg, once daily, orally, for a continuous period of 2 years.
Study: NCT06770608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: micro-needling with topical human actrapid insulin
Description: Micro-needling with topical application of 2ml of human actrapid insulin once monthly for 4 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-needling with topical Platelet rich plasma
Description: Micro-needling with topical application of 2ml Platelet rich plasma once monthly for 4 months
Study: NCT06771843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kisoboka
Description: Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance-free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol), Social support \& role models for financial goals and substance-free activities (delayed rewards, alternative reinforcers), Financial literacy, Develop motivation \& confidence for change, Goal setting for alcohol reduction \& ART adherence, Alcohol harms \& defining low risk drinking Discuss challenges to change and maintain alcohol risk reduction and improved adherence, Developing \& reinforcing discrepancy between savings/life goals and drinking/poor adherence, Developing discrepancy activity: goals for savings and healthy living and weekly, monthly, yearly spending on alcohol Self-monitoring of savings \& spending Text message reminders to reinforce discrepancy between unhealthy behavior \& goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Economics
Description: Intervention activities:~Financial goal setting (developing delayed rewards), Text message reminders of savings goals (increase salience of delayed rewards), Substance free activities (alternative reinforcers), Mobile money savings and work payments (constraints on buying alcohol/ decrease reward value of alcohol), Social support \& role models for financial goals and substance free activities (delayed rewards, alternative reinforcers), Financial literacy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Intervention activities:~Develop motivation and confidence for change, Specific goal setting for alcohol reduction and ART adherence, Alcohol harms \& defining low risk drinking, Discuss challenges to change and to maintain alcohol risk reduction and improved adherence/care engagement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and Referral
Description: Brief feedback on their Alcohol Use Disorders Identification Test (AUDIT) score per the AUDIT brief intervention manual, a referral for alcohol counseling, and brief guidance on the importance of HIV care engagement and adherence following the Ugandan Ministry of Health protocol. A referral coupon with details of the clinic name and location will be provided to each participant and participants will be asked to submit the referral note to the alcohol and/or HIV counselor.
Study: NCT06773325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Buzzy application
Description: Buzzy application during heel prick blood collection
Study: NCT06770335

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Full intervention
Description: A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm include the full intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THE FATIGUE, LEARNING, AND MEMORY ENRICHMENT (FLaME) INTERVENTION - Cognitive rehabilitation only
Description: A novel strategy-based cognitive rehabilitation intervention that can be delivered with or without cognitive fatigue management. Skills are targeted sequentially based on a developmental hierarchical model where cognitive fatigue can be addressed first, followed by adult-supported compensatory strategies, with independent use of strategies for specific impairments delivered only once these earlier levels have been addressed. The 'FLaME' program incorporates strategies that have been trialled and found successful in fatigue (e.g., pacing and activity scheduling) and cognitive rehabilitation (e.g., chunking, elaborative encoding techniques) interventions for children. The intervention address two key issues: 1) to deliver strategy-based cognitive rehabilitation as an alternative to prevailing drill-based approaches, and 2) to integrate fatigue management to improve feasibility and acceptability of cognitive rehabilitation. This arm includes the cognitive rehabilitation only.
Study: NCT06772558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane Inhalation
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.
Study: NCT06049901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide is considered a broad-spectrum anti-microbial drug with a potent activity against various helminths, anaerobic bacteria and viruses.
Study: NCT06772558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane Inhalation
Description: Anesthesia was maintained with either desflurane, with inhaled concentrations adjusted based on electroencephalogram (EEG) monitoring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation (MV)
Description: Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical ventilation (MV)
Description: Following induction, patients underwent mechanical ventilation in volume-controlled (VC) mode. Ventilation parameters were set using a GE Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA): tidal volume 6-8 ml/kg, positive end-expiratory pressure 0 cmH2O, inspiration/expiration ratio 1:2, respiratory rate 16 breaths/min, and inspired oxygen concentration of 41%.
Study: NCT06772441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: * Goserelin: AstraZeneca, 10.8mg injection~* ADT will be applied for 12 months in total~* ADT must be given concurrently and adjuvant
Study: NCT04870671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Description: Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC)
Description: Women will take 1 pill orally according the dosing regimen of the arm to which they are assigned
Study: NCT06774846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid/Aspirin (100 mg)
Description: Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
Description: patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.